Within-trial economic analysis of resource use from COMET-ICE: A phase 3 clinical trial evaluating sotrovimab for the treatment of patients with COVID-19 at high risk of progression

BACKGROUND: Final results for the primary endpoint of the COVID-19 Monoclonal antibody Efficacy Trial-Intent to Care Early (COMET-ICE) randomized controlled trial (NCT04545060) showed a 79% (P < 0.001) adjusted relative risk reduction in longer-than-24-hour hospitalization or death due to any cau...

Descripción completa

Detalles Bibliográficos
Autores principales: Lokhandwala, Tasneem, Acharya, Mahip, Farrelly, Eileen, Coutinho, Anna D, Bell, Christopher F, Svedsater, Henrik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372996/
https://www.ncbi.nlm.nih.gov/pubmed/36282931
http://dx.doi.org/10.18553/jmcp.2022.28.11.1261

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372996/
https://www.ncbi.nlm.nih.gov/pubmed/36282931
http://dx.doi.org/10.18553/jmcp.2022.28.11.1261

Ejemplares similares